Brief: Can-Fite Gears Up To Initiate Pivotal Phase III Liver Cancer Study
08/07/2021 12:16
July 8 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE GEARS UP TO INITIATE PIVOTAL PHASE III LIVER
CANCER
STUDY
* CAN FITE BIOPHARMA LTD - FDA GRANTED NAMODENOSON ORPHAN
DRUG AND
FAST TRACK STATUS
Source text for Eikon: ID:nBw8ZSWKCa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage